Sarah A. Buckley

Sarah A. Buckley

Auto-generated profile, based on publicly available information

Sarah A. Buckley

Hematology/Oncology Fellowship Program, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
SBSarah A. Buckley
Sarah A. Buckley
BWBrent L. Wood
Brent L. Wood
MOMegan Othus
Megan Othus
CHChristopher Hourigan
Christopher Hourigan
CUCelalettin Ustun
Celalettin Ustun
RWRoland B. Walter
Roland B. Walter
Minimal residual disease prior to allogeneic hematopoietic cell transplantation has been associated with increased risk of relapse and death in patients with acute myeloid leukemia, but detection methodologies and results vary widely. We performed a systematic review and meta-analysis evaluating the prognostic role of minimal residual disease detected by polymerase chain reaction or multiparametric flow cytometry before transplant. We identified 19 articles published between January 2005 and June 2016 and extracted hazard ratios for leukemia-free survival, overall survival, and cumulative incidences of relapse and non-relapse mortality. Pre-transplant minimal residual disease was associated with worse leukemia-free survival (hazard ratio=2.76 [1.90–4.00]), overall survival (hazard ratio=2.36 [1.73–3.22]), and cumulative incidence of relapse (hazard ratio=3.65 [2.53–5.27]), but not non-relapse mortality (hazard ratio=1.12 [0.81–1.55]). These associations held regardless of detection method, conditioning intensity, and patient age. Adverse cytogenetics was not an independent risk factor for death or relapse. There was more heterogeneity among studies using flow cytometry-based than WT1 polymerase chain reaction-based detection (I2=75.1% vs. <0.1% for leukemia-free survival, 67.8% vs. <0.1% for overall survival, and 22.1% vs. <0.1% for cumulative incidence of relapse). These results demonstrate a strong relationship between pre-transplant minimal residual disease and post-transplant relapse and survival. Outcome heterogeneity among studies using flow-based methods may underscore site-specific methodological differences or differences in test performance and interpretation.

1 January 2018 in Blood Reviews
Verified
Journal Article
Closed access
SBSarah A. Buckley
Sarah A. Buckley
KKKedar Kirtane
Kedar Kirtane
RWRoland B. Walter
Roland B. Walter
SLStephanie J. Lee
Stephanie J. Lee
GLGary H. Lyman
Gary H. Lyman

7 September 2017 in Cancer
Verified
Journal Article
Open access
PDF file
SBSarah A. Buckley
Sarah A. Buckley
DJDiana Jimenez‐Sahagun
Diana Jimenez‐Sahagun
MOMegan Othus
Megan Othus
Roland Bruno WalterRoland Bruno Walter
Roland Bruno Walter
SLStephanie J. Lee
Stephanie J. Lee
BACKGROUND: Although outcomes for acute myeloid leukemia (AML) have improved over time, they remain poor overall, and toxicity from both the disease and its treatment can affect quality of life (QOL). One barrier to including QOL endpoints in clinical trials is the lack of a disease‐specific QOL instrument that can efficiently capture the major QOL deficits in this population.METHODS: A cross‐sectional study was performed to elicit concepts for inclusion in a new AML‐specific QOL instrument called the AML‐QOL. Eighty‐two patients at various stages of disease were interviewed about sources of support (positive concepts) and problems and symptoms (negative concepts) experienced over the past week, and they were asked to grade how much each affected their QOL. In addition, patients were asked to complete 2 validated instruments: the Functional Assessment of Cancer Therapy with the leukemia and transplant modules and the 29‐item Patient‐Reported Outcomes Measurement Information System questionnaire.RESULTS: With data from the open‐ended and questionnaire‐based portions of the interview, 7 positive concepts and 64 negative concepts were elicited. From these, 5 positive concepts and 21 negative concepts were selected for inclusion in the preliminary AML‐QOL on the basis of concept prevalence and the impact on QOL.CONCLUSIONS: These concepts will form the basis of a new QOL instrument specific to AML. Cancer 2018;124:145‐52. © 2017 American Cancer Society.

25 July 2016 in Expert Review of Hematology
Verified
Journal Article
Closed access
SBSarah A. Buckley
Sarah A. Buckley
SLStephanie J. Lee
Stephanie J. Lee
RWRoland B. Walter
Roland B. Walter
(2016). Measuring quality of life in acute myeloid leukemia: limitations and future directions. Expert Review of Hematology: Vol. 9, No. 9, pp. 821-823.

1 February 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SBSarah A. Buckley
Sarah A. Buckley
JLJuan N. Lessing
Juan N. Lessing
NMNicholas M. Mark
Nicholas M. Mark

8 April 2015 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SBSarah A. Buckley
Sarah A. Buckley
RMRaya Mawad
Raya Mawad
TGTed A. Gooley
Ted A. Gooley
PBPamela S. Becker
Pamela S. Becker
VSVicky Sandhu
Vicky Sandhu
JPJohn M. Pagel
John M. Pagel